Bullfrog AI (NASDAQ:BFRG – Get Free Report) and Hims & Hers Health (NYSE:HIMS – Get Free Report) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, analyst recommendations, institutional ownership, risk, earnings, valuation and dividends.
Volatility & Risk
Bullfrog AI has a beta of 0.61, suggesting that its stock price is 39% less volatile than the S&P 500. Comparatively, Hims & Hers Health has a beta of 2.41, suggesting that its stock price is 141% more volatile than the S&P 500.
Valuation and Earnings
This table compares Bullfrog AI and Hims & Hers Health”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Bullfrog AI | $60,000.00 | 218.69 | -$6.99 million | ($0.69) | -1.67 |
| Hims & Hers Health | $2.21 billion | 4.12 | $126.04 million | $0.54 | 74.15 |
Hims & Hers Health has higher revenue and earnings than Bullfrog AI. Bullfrog AI is trading at a lower price-to-earnings ratio than Hims & Hers Health, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Bullfrog AI and Hims & Hers Health’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Bullfrog AI | N/A | -218.25% | -177.11% |
| Hims & Hers Health | 6.05% | 24.67% | 9.37% |
Insider and Institutional Ownership
1.0% of Bullfrog AI shares are owned by institutional investors. Comparatively, 63.5% of Hims & Hers Health shares are owned by institutional investors. 25.2% of Bullfrog AI shares are owned by insiders. Comparatively, 13.7% of Hims & Hers Health shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Analyst Ratings
This is a summary of current recommendations and price targets for Bullfrog AI and Hims & Hers Health, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Bullfrog AI | 1 | 0 | 0 | 0 | 1.00 |
| Hims & Hers Health | 3 | 10 | 2 | 0 | 1.93 |
Hims & Hers Health has a consensus price target of $45.27, suggesting a potential upside of 13.07%. Given Hims & Hers Health’s stronger consensus rating and higher probable upside, analysts clearly believe Hims & Hers Health is more favorable than Bullfrog AI.
Summary
Hims & Hers Health beats Bullfrog AI on 12 of the 14 factors compared between the two stocks.
About Bullfrog AI
Bullfrog AI Holdings, Inc., through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. The company offers bfLEAP, an analytical AI/ML platform for the analysis of preclinical and/or clinical data. It also has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for the use of a formulation of Mebendazole for the treatment of glioblastoma, and human cancer or neoplastic disease. The company was founded in 2017 and is based in Gaithersburg, Maryland.
About Hims & Hers Health
Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.
Receive News & Ratings for Bullfrog AI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bullfrog AI and related companies with MarketBeat.com's FREE daily email newsletter.
